Mindmaze

Six weeks after a stroke, a patient sits in a Mount Sinai outpatient clinic and reaches toward a virtual butterfly hovering above a digital meadow. Motion-tracking cameras capture every micro-movement of her hemiparetic arm, translating each gesture into game progress and quantified clinical data. What looks like play is, in fact, a high-dose, FDA-cleared therapy session running on infrastructure refined across more than a decade of clinical research, regulatory milestones, and engineering iteration. The platform powering this session is MindMaze, the Swiss-born digital neurotherapeutics company that has won a 2026 Global Recognition Award for category-defining work in brain technology. Following its December 2025 business combination, the company now operates as a publicly traded entity on the SIX Swiss Exchange with a valuation of approximately CHF 1.1 billion and a clinical evidence base documenting a 60% increase in delivered therapy per day across multi-site post-acute trials.

Technical Innovation and Architecture

MindMaze‘s platform is built around a multimodal sensing fabric that fuses 3D motion-tracking cameras, proprietary wearable peripherals, and gamified therapeutic content into a single regulated software stack. The company holds two FDA clearances, six CE marks, and a portfolio of more than 70 patent families covering motion analytics, mixed-reality therapeutics, facial-muscle signal translation through its Mask technology, and the Aatish smart peripheral for hand dexterity assessment. The MindMotion PRO and MindMotion GO products run the same therapeutic protocols across hospital, clinic, and home environments, with cloud-native telehealth integration that lets clinicians remotely supervise sessions and capture longitudinal adherence data. This architecture treats the brain not as a single-point intervention target but as a system requiring coordinated, dose-controlled stimulation across the recovery timeline.

The AI layer ingests multimodal data from thousands of patients across clinical and real-world deployments, with a federated learning roadmap, the EU AI Act principles, the GDPR, the EU Medical Device Regulation, and the EU General Data Protection Regulation, to personalize protocols, predict recovery trajectories, and optimize combinations of digital and pharmacological interventions. All AI components are developed in alignment with EU AI Act principles, GDPR, the EU Medical Device Regulation, and FDA Software as a Medical Device frameworks; the company holds ISO 13485 certification for medical device quality management. The result is not a point solution dressed in regulatory language; it is a regulated platform that few competitors in digital health have managed to assemble end-to-end. Where most digital therapeutics companies sell software, MindMaze sells a clinically validated, reimbursable continuum of care.

Market Strategy and Leadership

The commercial model blends SaaS licensing, proprietary peripheral hardware, and reimbursable services delivered across acute hospital, post-acute rehabilitation, outpatient, and home settings. The December 2025 business combination of NeuroX Group and Relief Therapeutics created MindMaze Therapeutics Holding SA. This publicly listed company pairs the digital therapeutics platform with established pharmaceutical commercial infrastructure and a portfolio of biopharmaceutical assets in rare dermatological and metabolic indications. The geographic playbook focuses on three reimbursement-ready markets: the United States, where Category III CPT codes for MindMotion support claims submission for tele-neurorehabilitation; Switzerland, where the company leads the SwissNeuroRehab consortium, funded by a CHF 11.2 million Innosuisse flagship grant; and the United Kingdom, where engagement aligns with the recipient of the Pfizer Foundation award, NICE clinical guidelines.

Leadership combines deep scientific lineage with commercial execution capacity. Founder Tej Tadi, an EPFL doctoral graduate, World Economic Forum Young Global Leader, and Pfizer Foundation award recipient, built the company from a Swiss spin-off into the country’s first technology unicorn. The post-merger executive team, led by Zach Henderson as CEO of MindMaze Therapeutics Holding SA and Alexandre Capet at the operating subsidiary, draws on commercial leadership recruited from US healthcare and pharmaceutical companies. Strategic partnerships with Johns Hopkins University School of Medicine, Mount Sinai Health System, the University of California, San Francisco, Lausanne University Hospital, EPFL, ETHZ, the Institute for the Brain and Spinal Cord, and Vibra Healthcare anchor both the research pipeline and the commercial flywheel. “Reimbursement is what allows innovation to reach patients at scale,” Capet has stated, framing the company’s strategic priority for the period ahead.

Industry Impact and Future Vision

The clinical impact is measurable and reproducible. A two-year, multi-site program with Vibra Healthcare reported statistically significant improvements in mobility and self-care, a 60% increase in delivered therapy per day, higher community discharge rates than standard of care, and 77% of patients reporting that the technology improved their recovery. Against a backdrop in which stroke alone affects approximately 800,000 people each year in the United States, and direct annual costs reach $22.8 billion, the ability to compress recovery timelines and extend therapy beyond clinic walls translates into measurable health system value. MindMaze’s products now serve patients across the United States, Switzerland, the United Kingdom, Germany, and Italy, with deployments at leading academic medical centers and a growing footprint in home-based care.

The forward roadmap targets multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer’s disease, alongside continued expansion of the US commercial footprint and broader utilization of the home-based therapy offering. The federated AI initiative will move the platform from pattern recognition to predictive personalization, modeling individual recovery trajectories and suggesting optimal therapeutic dosing in real time. Regulatory depth, evidence-grade clinical validation, public-market visibility, and a continuum-of-care platform that integrates pharmacological and digital interventions justify the 2026 Global Recognition Award. MindMaze has built what the digital therapeutics field has long promised: a scalable, reimbursable, clinically validated platform for brain health and recovery.